ProMIS NeurosciencesPMN +22.42%30 PB Ratio is 1.98 as of Jul. 01, 2026, which is 82% below its 10-year median of 10.99. GuruFocus rates PMN with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,229 Biotechnology companies, ProMIS Neurosciences ranks better than 69.89% on this metric.
ProMIS Neurosciences Inc stock PB Ratio (=1.59) is close to 10-year low of 1.59.
The historical rank and industry rank for ProMIS Neurosciences's PB Ratio or its related term are showing as below:
PMN'
s PB Ratio Range Over the Past 10 Years
Min: 1.59 Med: 10.99 Max: 158.19
Current: 1.94
During the past 13 years, ProMIS Neurosciences's highest PB Ratio was 158.19. The lowest was 1.59. And the median was 10.99.
PMN's PB Ratio is ranked better than 69.89% of 1229
companies
in the Biotechnology industry
Industry Median: 2.86
vs PMN: 1.94
During the past 12 months, ProMIS Neurosciences's average Book Value Per Share Growth Rate was -6.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 47.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ProMIS Neurosciences was 315.00% per year. The lowest was -88.30% per year. And the median was -21.70% per year.
Back to Basics: PB Ratio
ProMIS Neurosciences (NAS:PMN) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ProMIS Neurosciences PB Ratio Related Terms
ProMIS Neurosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for ProMIS Neurosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ProMIS Neurosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProMIS Neurosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where ProMIS Neurosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ProMIS Neurosciences (PMN) has a PB Ratio of 1.98 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ProMIS Neurosciences and its competitors. This is 82% below median its historical median of 10.99. Over the past decade, ProMIS Neurosciences' PB Ratio has ranged from 1.59 to 158.19. According to the industry distribution chart, ProMIS Neurosciences ranks #370 out of 1229 companies in the Biotechnology industry, placing it in the top 30.1%.
Is ProMIS Neurosciences' PB Ratio too high?
ProMIS Neurosciences' current PB Ratio of 1.98 is 82% below median its 10-year median of 10.99. Over the past 10 years, this metric has ranged from a low of 1.59 to a high of 158.19. The Biotechnology industry median PB Ratio is 2.86. ProMIS Neurosciences' value of 1.98 is 30.8% below this industry median. Based on the distribution chart, ProMIS Neurosciences ranks #370 out of 1229 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ProMIS Neurosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' PB Ratio compare to BMEA and ANIX?
According to the Biotechnology industry distribution chart, ProMIS Neurosciences ranks #370 out of 1229 companies for PB Ratio. This puts ProMIS Neurosciences in the upper half of its industry. The industry median PB Ratio is 2.86. ProMIS Neurosciences' value of 1.98 is 30.8% below this benchmark. Historically, ProMIS Neurosciences' own PB Ratio has ranged from 1.59 to 158.19 over the past decade. While the company's 10-year median is 10.99 vs. the industry median of 2.86, ProMIS Neurosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.86, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProMIS Neurosciences's current PB Ratio of 1.98 is 30.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ProMIS Neurosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProMIS Neurosciences's current PB Ratio is 1.98, which is 82% below median its own 10-year median of 10.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current PB Ratio of 1.98. The current PB Ratio is 1.98, which is 82% below median its 10-year median of 10.99 and 30.8% below the Biotechnology industry median of 2.86. ProMIS Neurosciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current PB Ratio is 1.98 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
30GF Score
Get the complete analysis for PMN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMN has been successfully added to your 
